Christian Chabannon

Hematologist. Stem cell transplantation and CAR-T Cells specialist. Jazz lover. Organ donor. Opinions are my own

[Mohamad Mohty @Mohty_EBMT]

Packed room. Endless enthusiasm. The IMWG Meeting in Stockholm is a powerful reminder that the myeloma community remains united by one mission: delivering better outcomes for all patients.

[JACIE @JACIE_EBMT]

📢 Now available: @FACTcelltherapy and #JACIE 9th Edition HCT Standards + 3rd Edition IEC Standards!

👏 A key milestone and example of the ongoing commitment to promoting high quality and patient safety in #HCT and #CellularTherapy worldwide. ⤵️  📌 https://t.co/hGHts5fY32

[JACIE @JACIE_EBMT]

🔍 FACT-JACIE Standards require alignment across Clinical, Collection, and Processing Units (B1.2 & C1.2).

☑️ All participating units must operate under certified conditions to ensure the highest standards of patient care and safety. 💡 Read more: https://t.co/cDmKQvsZ0H

[JACIE @JACIE_EBMT]

📘 Coming soon: A major milestone for the #HCT and #CellularTherapy community!

The new FACT-JACIE International Standards (HCT 9 and IEC 3) mark three years of global collaboration to advance quality, safety and best practice in cellular therapies. ⬇️
https://t.co/hGHts5fqdu

[Mohamad Mohty @Mohty_EBMT]

Celebrating 35 years of academic excellence!
The IFM has led groundbreaking trials shaping the modern era of high-dose therapy in myeloma. Proud to see this legacy highlighted in ⁦@BloodCancerJnl⁩ , showcasing how IFM research has set global standards for myeloma care.

[EBMT @TheEBMT]

🧬 We unite with key stakeholders across the European healthcare ecosystem to safeguard the #HospitalExemption for Advanced Therapy Medicinal Products (ATMPs).

📣 This Joint Position Statement puts forward the key recommendations to secure a fair, balanced, and effective regulatory environment for HE-ATMPs — one that sustains innovation, protects patient access, and strengthens Europe’s capacity to deliver advanced therapies for all.

Read more ⬇️
🔗 https://t.co/ht3enr8iZ7

[IACH @TheIACH]

🏆𝘁𝗵𝗲 𝗜𝗔𝗖𝗛 𝟮𝟬𝟮𝟱 𝗔𝘄𝗮𝗿𝗱 𝗖𝗲𝗿𝗲𝗺𝗼𝗻𝘆 𝘛𝘩𝘦 𝘳𝘦𝘤𝘪𝘱𝘪𝘦𝘯𝘵 𝘰𝘧  𝘁𝗵𝗲 𝗖𝗵𝗿𝗶𝘀𝘁𝗶𝗮𝗻 𝗖𝗮𝗶𝗹𝗹𝗶𝗼𝘁 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗔𝘄𝗮𝗿𝗱 is 𝗣𝗿𝗼𝗳. 𝗔𝗻𝗻𝗮𝗹𝗶𝘀𝗮 𝗥𝘂𝗴𝗴𝗲𝗿𝗶 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴!

@Mohty_EBMT @nagler_EBMT @TheIACH

#IACH #Hematology #Myeloma #Lymphoma #MPN #CellTherapy #StemCellTransplant

[Nicolas Cadène 🌍 @ncadene]

#Badinter #Panthéon
«Le fascisme ne se lève pas comme la tempête en une nuit. D’abord rampant, dissimulé, ordinaire, il progresse par les voix de la haine, avivée par les difficultés économiques. Il s’empare des cœurs avant de pervertir les esprits puis de prendre le pouvoir»☝️

[EBMT @TheEBMT]

🗓️ The 3rd Practice Harmonisation and Guidelines Committee meeting took place in Berlin end of September, bringing together experts from across Europe and beyond. 🌐 With:

👩‍🏫 12 parallel workshops
👥 100+ participants from
🌍 22 countries,

This event fostered collaboration, advancing dialogue and pratice harmonisation in #HCT and #CellTherapy.

Thank you to everyone who joined!

#MedicalGuidelines #Collaboration #Research

[Satya Prakash Yadav @Satyayadav__]

Let’s cut it out - HIV from cells CRISPER ly

[Mohamad Mohty @Mohty_EBMT]

A World First in Hematology Education
⁦@TheIACH⁩ is proud to announce the first-ever AI-generated live webinar in hematology.
Harnessing the power of AI, this event will deliver a glimpse into the future.
Join us at this historic milestone where innovation meets hematology.

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

Gamma delta (γδ) T cells, constituting 5%–10% of peripheral blood lymphocytes, are pivotal in tumor immunosurveillance and are enriched in epithelial tissues. Their unique antigen recognition makes them ideal for allogeneic cell therapy products, with several clinical trials currently underway. This comprehensive review provides an overview of the rationale for γδ T-cell therapy, ongoing clinical trials, as well as the challenges and future role of γδ T-cell-based immune therapies in hematology.

Read in-depth here👉https://t.co/CelUAbwcF1

[EBMT @TheEBMT]

📣 Register early and submit your abstract for #EBMT26 – join us in Madrid for Europe’s largest congress in #HCT and #CellTherapy.

📽️ Hear the welcome from @RDuarte_EBMT and Isabel Salcedo
📌 Check out Early Bird discounts, and
🌍 Get ready to connect with 6,200+ colleagues from across the globe in March 2026. ⬇️
https://t.co/7icdCJdCYc

[EBMT @TheEBMT]

🎉 Celebrating the anniversary of the EBMT Registry

Since the current system went live in August 2023:
📊 65,000+ new patients added
📈 790,000+ total patient records
💡 73,400+ treatments registered

Thank you to our community for making this possible! 🌍 Read more about the milestone ⬇️
https://t.co/HXm0FbaALl

#EBMTRegistry #HCT #CellTherapy #ClinicalResearch #PatientCare

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

Patients with relapsed or refractory primary or secondary CNS lymphoma face a poor prognosis. This study of 100 patients treated with anti-CD19 CAR T-cell therapy showed promising results, supporting its use for these patients despite the risk of severe neurotoxicity.

Read more👉https://t.co/sMrE7G2fhW

[Hematologia ICO Hospitalet @HematICO_Hosp]

The last @CIBMTR @TheEBMT publication!
#ICOnic @AnnaSureda5 participation!

https://t.co/743Q4bigZg

[Christian Chabannon @CChabannon]

@TheEBMT @TheEBMT_Trainee As we celebrate the 10th Anniversary of ITCTC, it is important to remember the key role played by @RDuarte_EBMT & @Mohty_EBMT in launching this educational initiative designed to attract and educate younger generations of HCP, then disruptive, today a classic! Thanks.

[DrOlivierBoyer @DrOlivierBoyer]

Didn't register yet? Don't miss the CAR-T day

[Jordan Gauthier @drjgauthier]

I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇
https://t.co/5JtisXr3Tz
🔑 findings:
💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes.
💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%).
💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity.

❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL

🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X.
Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅

👉Please share with your network if you learnt something with this post 🙏
#HemOnc #MedEd #lymphomasm #CARTcelltherapy

[European Hematology Association @EHA_Hematology]

New #EHAUnplugged episode available now - Managing Young Fit AML patients.

President of EHA, Prof Konstanze Döhner, discusses the most recent developments in the management of young and fit patients with AML. Hear about the diagnostic workup, risk stratification, treatment, and the evolving role of MRD measurements in clinical decision making in AML patients. 

Find us on Spotify, Apple Podcasts, YouTube, and major podcast platforms: https://t.co/7UswUNC3DR